Meeting Banner
Abstract #3097

Glioma staging with CEST asymmetry curves and amides/amines ratio.

Laura Mancini1,2, Stefano Casagranda3, Francisco Torrealdea4, Marilena Rega4, Enrico De Vita1,5, Bruno Lopez3, Sebastian Brandner6,7, Benjamin Schmitt8, Patrick Liebig8, Eser Sanverdi1, Xavier Golay1,2, and Sotirios Bisdas1,2
1Lysholm Dept of Neuroradiology, National Hospital for Neurology & Neurosurgery, UCL Hospitals NHS Foundation Trust, London, United Kingdom, 2UCL Institute of Neurology, London, United Kingdom, 3Olea Medical, La Ciotat, France, 4University College of London Hospitals NHS Foundation Trust, London, United Kingdom, 5Biomedical Engineering Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom, 6Department of Neurodegenerative Disease, Institute of Neurology UCL, London, United Kingdom, 7National Hospital for Neurology & Neurosurgery, UCL Hospitals NHS Foundation Trust, London, United Kingdom, 8Siemens Healthcare Limited, Erlangen, Germany

Gliomas are the most common primary brain tumour, whose staging depends on the IDH and 1p/19q status and is reflected in different prognoses and clincal management. CEST is a highly sensitive MRI technique detecting amide- and amine-containing mobile proteins. The CEST amides/amines ratio has been proposed as a measure of pH in stroke. We show that CEST amides/amines ratio is much more sensitive than separate amides and amines CEST in differentiating gliomas with the best prognosis (IDH-mutant_1p/19q-retained) from those with the worst prognosis (IDH-wildtype). The different shapes in CEST asymmetry spectra could also potentially help in glioma staging.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here